Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $69.67M |
| Gross Profit (TTM) | $8.84M |
| EBITDA | $-104.60M |
| Operating Margin | -150.20% |
| Return on Equity | -50.30% |
| Return on Assets | -25.00% |
| Revenue/Share (TTM) | $0.71 |
| Book Value | $2.21 |
| Price-to-Book | 6.38 |
| Price-to-Sales (TTM) | 21.29 |
| EV/Revenue | 19.02 |
| EV/EBITDA | -0.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.00% |
| Shares Outstanding | $106.80M |
| Float | $72.33M |
| % Insiders | 26.15% |
| % Institutions | 66.66% |
Volatility is currently contracting
MONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) (“Personalis”) to Tempus AI, Inc. (“Tempus”) for $16.25 per share.
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https://julieholleman.com/personalis-inc/.
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, July 21, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Personalis, Inc. (NASDAQ: PSNL ) related to its sale to Tempus AI, Inc. Under the terms of the proposed transaction, Personalis shareholders are expected to receive $16.25 per share of common stock.
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Personalis, Inc. (PSNL) M&A Call Transcript
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Personalis, Inc. (NASDAQ: PSNL) to Tempus AI, Inc. for $16.25 per share of common stock. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect payment in cash at Tempus' discretion, capped at 50% of the consideration paid.Halper Sadeh encourages Personalis shareholders to click here to learn more about their rights and options or cont.
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PSNL and any ticker you trade — then tracks every position and per-strategy win rate.
